Western Companies Pfizer updated its public R&D pipeline on 4 November 2025, highlighting late-stage vaccine assets (including RSV, meningococcal, and next-generation COVID products) while signaling a more selective approach to new vaccine investments as the COVID market normalizes. Source: Pfizer News Moderna’s 5 November 2025 earnings update reported declining COVID and RSV vaccine sales, a narrowed 2025 revenue forecast (now roughly US$1.6–2.0 billion), and a greater strategic emphasis on cost control and advancing its broader mRNA pipeline (oncology, latent viruses, and combined respiratory vaccines). Source: Moderna News Reuters reported on 13 November that Pfizer substantially reduced its equity stake in BioNTech, several years after their COVID-19 collaboration peak, as part of a broader portfolio and capital reallocation strategy, while the companies continue to cooperate on marketed products. Source: Reuters Industry monitoring from late November notes continued restructuring and deal-making by Western manufacturers, such as Novavax’s portfolio streamlining in the US and Sanofi’s acquisition of Vicebio earlier in...
🔒 Premium Content - For Free
Unlock this content by becoming a Global Health Press subscriber. Join for exclusive articles, expert research, and valuable insights!
